R. Lor Randall, MD, FACS, discusses the early efficacy seen with both vimseltinib monotherapy and pexidartinib plus surgery in patients with previously unresectable or inoperable diffuse tenosynovial giant cell tumors.
R. Lor Randall, MD, FACS, emphasizes the overall potential for investigating the utility of engineered bone marrow in patients with osteosarcoma, which highlights the ongoing research that is being conducted at the University of California Davis Comprehensive Cancer Center.
New research led by a UC Davis Comprehensive Cancer Center clinical scientist shows blood tests used to hunt for cancer DNA may help detect cancers faster and guide the use of targeted therapies.